Lupin jumps on inking pact to acquire Medisol
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 721.05, up by 16.40 points or 2.33% from its previous closing of Rs. 704.65 on the BSE.
The scrip opened at Rs. 705.25 and has touched a high and low of Rs. 724.60 and Rs. 704.05 respectively. So far 30533 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 788.90 on 23-Dec-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 727.50 and Rs. 702.20 respectively. The current market cap of the company is Rs. 32552.55 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance.
Founded in 2011, Medisol specializes in Generics Injectable products and is engaged in developing and commercializing its products in France, in pharmacies and in hospitals. With this acquisition, Lupin will gain access to Medisol’s portfolio of seven injectable products across four therapeutic areas, including pain management, anti-inflammatory, cardiovascular diseases, and obstetrics.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
.jpg)
